

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

In re Entresto (Sacubitril/Valsartan) Patent Litigation

C.A. No. 20-2930-RGA

NOVARTIS PHARMACEUTICALS
CORPORATION,

Plaintiff,

V.

C.A. No. 19-2053-RGA

HETERO USA INC., HETERO LABS LIMITED, HETERO LABS LIMITED UNIT III, MSN PHARMACEUTICALS INC., MSN LABORATORIES PRIVATE LIMITED, MSN LIFE SCIENCES PRIVATE LIMITED,

Defendants.

STIPULATION AND [PROPOSED] ORDER TO EXTEND TIME

IT IS HEREBY STIPULATED AND AGREED, by the parties, subject to the approval of the Court, that the deadline to file public, redacted version of Novartis's and Hetero's Joint Motion to Vacate Judgment as to Hetero Pursuant to Federal Rules of Civil Procedure 62.1 and 60(b) (D.I. 1419 in C.A. No. 20-2930; D.I. 419 in C.A. No. 19-2053) is extended to August 14, 2024 (from August 7, 2024).

Dated: August 7, 2024

MCCARTER & ENGLISH, LLP

/s/ Alexandra M. Joyce
Daniel M. Silver (#4758)
Alexandra M. Joyce (#6423)
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, Delaware 19801
(302) 984-6300
dsilver@mccarter.com
ajoyce@mccarter.com

*Attorneys for Plaintiff
Novartis Pharmaceuticals Corporation*

SMITH, KATZENSTEIN & JENKINS LLP

/s/ Daniel A. Taylor
Neal C. Belgam (# 2721)
Daniel A. Taylor (# 6934)
1000 West Street, Suite 1501
Wilmington, DE 19801
(302) 652-8400
nbelgam@skjlaw.com
dtaylor@skjlaw.com

*Attorneys for Defendants
Hetero USA Inc., Hetero Labs Limited,
Hetero Labs Limited Unit III.*

SO ORDERED this _____ day of _____, 2024.

UNITED STATES DISTRICT JUDGE